Eurofins Expands Its Clinical Diagnostic Footprint with the Acquisition of VRL Laboratories in the USA
September 01 2016 - 1:30AM
Business Wire
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), a global leader in bio-analytical
testing, and one of the world leaders in genomic services,
announces the acquisition of VRL Laboratories (“VRL”), one of the
leading laboratories in pre-transplant testing for the eligibility
determination for Donors of Human Cells, Tissues, and Cellular and
Tissue-Based Products (HCT/Ps) in the US.
Founded in 2010, VRL has become a reference laboratory solely
focused on donor eligibility testing and microbiology testing for
the transplant and medical communities. The company offers a broad
menu of infectious disease screening assays to support the FDA’s 21
CFR 12711 donor eligibility determination testing requirements,
specifically for eye, tissue, organ, stem cell and cord blood, as
well as reproductive tissues. VRL employs a total of 60 staff
across its main facility in Denver CO, and its satellite
laboratories in Boston, MA, Dallas, TX, and Atlanta, GA.
The acquisition of VRL reinforces Eurofins’ footprint in
specialty clinical testing services and consolidates the Group’s
leadership in the transplantation testing market. Furthermore,
VRL’s microbiology testing services expands Eurofins’ testing
portfolio and increases client penetration in the transplantation
testing market. In return, VRL will have access to the Group’s
clients and competencies, as well as its laboratory network
infrastructure, which should support its further development.
Comment from Dr. Gilles Martin, Eurofins CEO: “The
acquisition of VRL is another demonstration of our strategy of
expanding and strengthening our network of competence centers. In
combination with ViraCor and Diatherix, VRL reinforces the Group’s
footprint in the testing market for transplantation and infectious
diseases.”
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins believes it is the world leader in food, environment
and pharmaceutical products testing and that it is also one of the
global independent market leaders in certain testing and laboratory
services for agroscience, genomics and discovery pharmacology and
for supporting clinical studies. In addition, Eurofins is one of
the significant emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With 25,000 staff in more than 250 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
1 FDA Code of Federal Regulations #21: Human cells, tissues and
cellular and tissue-based products
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160831006234/en/
For more information, please visit
www.eurofins.com or contact:Eurofins Investor
RelationsPhone: +32-2-766 1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Oct 2023 to Oct 2024